I wouldn't be disappointed if Vyera breached the c
Post# of 145516
![](/assets/46931549/no_avatar_available_thumb.jpg)
I did the same DD and understood the intrinsic value of the royalty structure -- but I cannot think of a worse pharma company to align with from an optics point-of-view.
Lastly, since Vyera has rights to all domestic HIV indications, I have to believe that CytoDyn becomes a much more attractive [ licensing, partnership, acquisition ] target for BP if they are not in the picture.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)